20 Jan 2021 15:02
GlaxoSmithKline plc (the 'Company')
Â
Transaction notification
Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms E Walmsley | |||
b) | Position/status | Chief Executive Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | £13.9340 | 920 |  | ||
 | £13.9340 | 924 |  | ||
 | £13.9340 | 740 |  | ||
 |  |  |  | ||
d) | Aggregated information  | 2,584 | |||
 Aggregated volume Price |  £13.9340 | ||||
e) | Date of the transaction | 2021-01-18 | |||
f) | Place of the transaction  | London Stock Exchange (XLON) |
Â
Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dr H Barron | |||
b) | Position/status | Chief Scientific Officer and President, R&D | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 Â | |||
b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 14 January 2021 on ADSs held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | $38.1600 | 539 |  | ||
 | $38.1600 | 423 |  | ||
 |  |  |  | ||
d) | Aggregated information  | 962 | |||
 Aggregated volume Price |  $38.1600 | ||||
e) | Date of the transaction | 2021-01-18 | |||
f) | Place of the transaction  | New York Stock Exchange (XNYS) |
Â
 Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr R Connor  | |||
b) | Position/status | President, Global Vaccines | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | £13.9340 | 195 |  | ||
 | £13.9340 | 241 |  | ||
 | £13.9340 | 233 |  | ||
 |  |  |  | ||
d) | Aggregated information  | 669 | |||
 Aggregated volume Price |  £13.9340 | ||||
e) | Date of the transaction | 2021-01-18 | |||
f) | Place of the transaction  | London Stock Exchange (XLON) |
Â
 Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms D Conrad | |||
b) | Position/status | SVP Human Resources | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | £13.9340 | 96 |  | ||
 |  |  |  | ||
d) | Aggregated information  | N/A (single transaction) | |||
 Aggregated volume Price |  | ||||
e) | Date of the transaction | 2021-01-18 | |||
f) | Place of the transaction  | London Stock Exchange (XLON) |
Â
 Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr J Ford | |||
b) | Position/status | Senior Vice President and General Counsel | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | £13.9340 | 137 |  | ||
 |  |  |  | ||
d) | Aggregated information  | N/A (single transaction) | |||
 Aggregated volume Price |  | ||||
e) | Date of the transaction | 2021-01-18 | |||
f) | Place of the transaction  | London Stock Exchange (XLON) |
Â
Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr J Ford | |||
b) | Position/status | Senior Vice President and General Counsel | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 Â | |||
b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 14 January 2021 on ADSs held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | $38.1600 | 46 |  | ||
 |  |  |  | ||
d) | Aggregated information  | N/A (single transaction) | |||
 Aggregated volume Price |   | ||||
e) | Date of the transaction | 2021-01-18 | |||
f) | Place of the transaction  | New York Stock Exchange (XNYS) |
Â
 Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr N Hirons | |||
b) | Position/status | SVP, Global Ethics & Compliance | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | £13.9340 | 102 |  | ||
 | £13.9340 | 72 |  | ||
 | £13.9340 | 101 |  | ||
 |  |  |  | ||
d) | Aggregated information  | 275 | |||
 Aggregated volume Price |  £13.9340 | ||||
e) | Date of the transaction | 2021-01-18 | |||
f) | Place of the transaction  | London Stock Exchange (XLON) |
Â
 Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms S Jackson | |||
b) | Position/status | SVP, Global Communications & CEO Office | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | £13.9340 | 58 |  | ||
 |  |  |  | ||
d) | Aggregated information  | N/A (single transaction) | |||
 Aggregated volume Price |   | ||||
e) | Date of the transaction | 2021-01-18 | |||
f) | Place of the transaction  | London Stock Exchange (XLON) |
Â
 Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr I Mackay | |||
b) | Position/status | Chief Financial Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | £13.9340 | 499 |  | ||
 |  |  |  | ||
d) | Aggregated information  | N/A (single transaction) | |||
 Aggregated volume Price |   | ||||
e) | Date of the transaction | 2021-01-18 | |||
f) | Place of the transaction  | London Stock Exchange (XLON) |
 Â
Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr B McNamara | |||
b) | Position/status | CEO, GSK Consumer Healthcare | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 Â | |||
b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 14 January 2021 on ADSs held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | $38.1600 | 90 |  | ||
 | $38.1600 | 96 |  | ||
 | $38.1600 | 78 |  | ||
 |  |  |  | ||
 |  |  |  | ||
d) | Aggregated information  | 264 | |||
 Aggregated volume Price |  $38.1600 | ||||
e) | Date of the transaction | 2021-01-18 | |||
f) | Place of the transaction  | New York Stock Exchange (XNYS) |
Â
Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr L Miels | |||
b) | Position/status | President, Global Pharmaceuticals | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | £13.9340 | 185 |  | ||
 | £13.9340 | 224 |  | ||
 | £13.9340 | 256 |  | ||
 |  |  |  | ||
d) | Aggregated information  | 665 | |||
 Aggregated volume Price |  £13.9340 | ||||
e) | Date of the transaction | 2021-01-18 | |||
f) | Place of the transaction  | London Stock Exchange (XLON) |
 Â
Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr D Redfern | |||
b) | Position/status | Chief Strategy Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | £13.9340 | 190 |  | ||
 | £13.9340 | 228 |  | ||
 | £13.9340 | 164 |  | ||
 |  |  |  | ||
d) | Aggregated information  | 582 | |||
 Aggregated volume Price |  £13.9340 | ||||
e) | Date of the transaction | 2021-01-18 | |||
f) | Place of the transaction  | London Stock Exchange (XLON) |
Â
 Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr R Simard | |||
b) | Position/status | President, Pharmaceuticals Supply Chain | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | £13.9340 | 82 |  | ||
 | £13.9340 | 116 |  | ||
 |  |  |  | ||
d) | Aggregated information  | 198 | |||
 Aggregated volume Price |  £13.9340 | ||||
e) | Date of the transaction | 2021-01-18 | |||
f) | Place of the transaction  | London Stock Exchange (XLON) |
Â
 Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms K Terrell | |||
b) | Position/status | Chief Digital & Technology Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 Â | |||
b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 14 January 2021 on ADSs held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | $38.1600 | 32 |  | ||
 | $38.1600 | 114 |  | ||
 | $38.1600 | 79 |  | ||
 |  |  |  | ||
d) | Aggregated information  | 225 | |||
 Aggregated volume Price |  $38.1600 | ||||
e) | Date of the transaction | 2021-01-18 | |||
f) | Place of the transaction  | New York Stock Exchange (XNYS) |
 Â
Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr P Thomson | |||
b) | Position/status | President, Global Affairs | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | £13.9340 | 128 |  | ||
 | £13.9340 | 133 |  | ||
 | £13.9340 | 94 |  | ||
 |  |  |  | ||
d) | Aggregated information   | 355 | |||
Aggregated volume Price | £13.9340 | ||||
e) | Date of the transaction | 2021-01-18 | |||
f) | Place of the transaction  | London Stock Exchange (XLON) |
Â
Â